WeVote
Log In

Bill

Bill

H 1324

An Act relative to prescription drug pricing

194th Legislature (2025-2026) Introduced by Alan Silvia

Massachusetts bill H 1324 addresses prescription drug pricing through regulatory mechanisms to reduce medication costs, currently advancing through healthcare financing committee review.

Reporting date extended to Friday, July 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 1324

Legislative bill overview

H 1324 proposes regulatory changes to address prescription drug pricing in Massachusetts, though the specific mechanisms are not detailed in the available legislative record. The bill has progressed through multiple committee referrals and received a favorable committee report, indicating legislative movement toward addressing drug cost concerns.

Why is this important

Prescription drug costs are a significant burden for Massachusetts residents and state healthcare budgets. Any legislation targeting drug pricing could affect medication affordability, insurance premiums, and overall healthcare spending across the state's population and public programs.

Potential points of contention

  • Scope of price regulation: Unclear whether the bill would regulate all drugs, specific categories, or only state-purchased medications—each approach carries different implementation challenges and market impacts
  • Manufacturer vs. middleman focus: Disagreement likely exists over whether pricing controls should target pharmaceutical companies directly or intermediaries like pharmacy benefit managers (PBMs)
  • Federal-state jurisdiction: Questions about whether Massachusetts can independently regulate drug pricing without conflicting with federal law and interstate commerce considerations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.